Skip to Main Content (Press Enter)
×
Home
Corsi
Insegnamenti
Professioni
Persone
Pubblicazioni
Strutture
Terza Missione
Attività
Competenze
IT
EN
☰
UNI-FIND
|
UNI-FIND
uninsubria.it
IT
EN
×
Home
Corsi
Insegnamenti
Professioni
Persone
Pubblicazioni
Strutture
Terza Missione
Attività
Competenze
☰
Pubblicazioni
JOURNAL FOR IMMUNOTHERAPY OF CANCER
Rivista
Codice:
E225389
ISSN:
2051-1426
Dati Generali
Dati Generali
Pubblicazioni (9)
A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy
Articolo
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation
Articolo
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer
Articolo
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry
Articolo
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy
Articolo
INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A multicenter prospective observational study (INVIDIa-2)
Articolo
Integrating interferon gamma receptor pathways, antigenicity, and immune contexture as predictors of immunotherapeutic strategies for mucosal melanomas
Articolo
The IL-1/IL-1 receptor axis and tumor cell released inflammasome adaptor ASC are key regulators of TSLP secretion by cancer associated fibroblasts in pancreatic cancer
Articolo
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry
Articolo
No Results Found
